Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Dario Lemos, Ph.D.

Title
Institution
Department
Address
Profile Picture

Biography
education and training
University of British Columbia, Canada01/2015Tissue regeneration
Oregon Health and Science University, USPh.D.11/2008Molecular physiology
Biogen, US10/2016Tissue injury and regeneration
awards and honors
2004 - 2005
Fogarty International Scholarship
2001 - 2002
Undergraduate Student Research Scholarship
2019 - 2019
Department of Medicine Chair's Research Award

Overview
overview
Biomedical researcher with expertise in mechanisms of tissue regeneration and stem cell biology

Research
research activities and funding
The research activities and funding listed below are automatically derived from NIH ExPORTER and other sources, which might result in incorrect or missing items. Faculty can login to make corrections and additions.
Most Recent  |  List All
  1. (Dario Lemos) Jul 1, 2023 - Jun 30, 2024
    Brigham Research Institute-Fund to Sustain Research Excellence
    Mechanisms of renal angiomyolipoma in Tuberous Sclerosis Complex
    Role Description: A majority of patients with Tuberous Sclerosis Complex (TSC) develop kidney tumors known as angiomyolipomas (AMLs) that can cause renal insufficiency and spontaneous life-threatening bleedings, resulting in premature death. The mechanisms of AML initiation and growth remain unknown, partly because of the lack of proper tools to study these tumors in the laboratory. We will investigate the origin and formation of AMLs using miniature AMLs recreated in our laboratory using patient-derived induced pluripotent stem cells, with which we will examine individual cells with the goal of identifying targets for future therapies.
    Role: PI
  2. (Dario Lemos) Jul 1, 2023 - Jun 30, 2024
    Paul Teschan Research Fund
    Secondary use of induced pluripotent stem cells for generation of kidney tissues - Novel therapies for Tuberous Sclerosis Complex-Associated renal angiomyolipoma
    Role Description: Angiomyolipoma (AML) growth can cause renal insufficiency and lead to chronic kidney failure in patients with Tuberous Sclerosis Complex (TSC). Everolimus is the main treatment for AML, however orally administered free drug has only 40%-50% efficacy in reducing tumor size and can cause multiple adverse effects. In this project we will use AML organoids generated from induced pluripotent stem cells, as the experimental platform to identify mechanisms of tumor resistance and to test a novel nanocarrier-based approach for AML-targeted drug delivery as a pharmacologic strategy to increase anti-tumor efficacy and reduce adverse effects.
    Role: PI
  3. R01CA269583 (Dario Lemos) Jun 1, 2023 - May 31, 2028
    NIH/NCI
    Elucidation Tumor Resistance Mechanisms in Tuberous Sclerosis Complex-Associated Renal Angiomyolipoma for the Design of Novel Nanotherapies
    Role Description: A majority of patients with Tuberous Sclerosis Complex (TSC) develop kidney angiomyolipomas (AMLs) that can cause renal insufficiency and life-threatening spontaneous hemorrhages, for which the only current therapy is everolimus. Everolimus has limited anti-tumor efficacy, and tumor re-growth frequently occurs after treatment is interrupted due to side effects. In order to investigate the mechanisms of tumor resistance to everolimus therapy, we have generated AML tissues from patient-derived induced pluripotent stem cells, which we will use to test novel therapies with increased efficacy.
    Role: PI
  4. R01DK124301 (LEMOS, DARIO) Apr 9, 2020 - Mar 31, 2023
    NIH
    Inflammatory Signaling in Kidney Stromal Cells Driving Interstitial Fibrosis
    Role Description: A majority of patients with Tuberous Sclerosis Complex (TSC) develop kidney angiomyolipomas (AMLs) that can cause renal insufficiency and life-threatening spontaneous hemorrhages, for which the only current therapy is everolimus. Everolimus has limited anti-tumor efficacy, and tumor re-growth frequently occurs after treatment is interrupted due to side effects. In order to investigate the mechanisms of tumor resistance to everolimus therapy, we have generated AML tissues from patient-derived induced pluripotent stem cells, which we will use to test novel therapies with increased efficacy.
    Role: PI
  5. R21AG058159 (LEMOS, DARIO) Jul 1, 2018 - Mar 31, 2020
    NIH
    Detection of aging mechanisms of nephron degeneration using nanoscale pathology
    Role Description: The goal of this project is to test, in collaboration with the MIT Media Lab, the use of Expansion Microscopy for the early detection of aging-associated changes in the nephron microenvironment in relation to the adoption of a secretory senescent phenotype in epithelial cells of the proximal tubule
    Role: Principal Investigator

Bibliographic
selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
Updating...
This operation might take several minutes to complete. Please do not close your browser.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Lemos's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (191)
Explore
_
Co-Authors (15)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
© 2025 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.